Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNIPER-LTFU long-term follow-up study of RR001-treated patients from the parent SNIPER trial
2026-525714-59-00Phase 2Authorised
- Sponsor
- EIR Biotherapies
- Start
- Oct 2026
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RR001 in pancreatic adenocarcinoma (PDAC), sponsored by EIR Biotherapies. Primary endpoint: Incidence of long-term safety events. Planned start Oct 2026; status: authorised.
02
Drugs
RR001
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2026-525714-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525714-59-00.